On October 9th,Boston Science announced that it would establish the first production and manufacturing base in China in Shanghai.Boston Science stated that the company's self built production and manufacturing base plans to be located in the Life Blue Bay Pharmaceutical Characteristic Industrial Park in the Lingang New Area.In the future,the medical devices produced by the base will focus on supplying the Chinese market,and domestic manufacturing will help improve the accessibility of cutting-edge medical technologies.
According to Shangguan News,on the same day,Shanghai Municipal Party Secretary Chen Jining met with Ma Hongming,the global chairman and CEO of Boston Science Corporation in the United States.Chen Jining stated that biopharmaceuticals are one of the three leading industries vigorously developed in Shanghai.We are committed to creating a market-oriented,legalized,and internationalized first-class business environment,building a regulatory system that is compatible with high-level openness,and providing more precise policy supply and efficient service docking to help global enterprises innovate and develop in Shanghai.Boston Science Corporation is a leading minimally invasive medical device company in the world.We welcome the closer integration of our own advantages with Shanghai's rich medical resources,comprehensive industrial support,active technological innovation,and advanced institutional measures.We will increase investment,research and development,and production layout in Shanghai,continuously improve our business capabilities,and place more new products,technologies,and production manufacturing in Shanghai to incubate and drive more innovative enterprises to grow together.
Ma Hongming introduced the business development and future development plans of Boston Science in Shanghai.He stated that enterprises have made significant progress in their development in Shanghai,their commitment to the Chinese market has never changed,and they are full of confidence in China's future development.We will continue to increase investment,place more research and development,training,clinical research,and production manufacturing in Shanghai,deepen practical cooperation with Chinese partners,and make positive contributions to promoting the development of the life and health industry.
Currently,with the deepening of localization,Boston Science's business in China is expanding up and down the industrial value chain.Previously,Boston Scientific completed the local production of an intravascular ultrasound system through the pilot implementation of the Medical Device Registration System(MAH)in Shanghai.At present,the product has achieved a three-step process of"transitioning from import to domestic production and then to export",and the first prototype of its latest replacement product has also been taken offline in Shanghai.Last year,Boston Science also achieved the localization of innovative products through technology transfer and strategic distribution cooperation.
However,Boston Science did not provide specific information on the investment scale and schedule planning of the above-mentioned production base.For these questions,reporters from the Daily Economic News also conveyed their interview demands to Boston Science,and the company stated that"they are currently unable to answer these questions".